+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Stem Cell Assay Market Report and Forecast 2024-2032

  • PDF Icon


  • 140 Pages
  • April 2024
  • Region: Global
  • Expert Market Research
  • ID: 5960379

Global Stem Cell Assay Market Overview

The global stem cell assay market size was valued at USD 6.4 billion in 2023 and is expected to reach USD 19.4 billion by 2032, growing at a compound annual growth rate (CAGR) of 13.18% during the forecast period of 2024-2032.

Stem cell assay is a technique used to measure the properties and functions of stem cells, such as viability, proliferation, differentiation, and self-renewal. Stem cell assay has various applications in drug discovery, regenerative medicine, and cell therapy. The major factors driving the growth of the market are the increasing investments in stem cell research, the rising prevalence of chronic diseases, and the growing demand for stem cell-based therapies. However, the market also faces some challenges, such as ethical and regulatory issues, the high cost of stem cell products, and the lack of standardized procedures and infrastructure for stem cell assay.

Global Stem Cell Assay Market Drivers and Constraints

Some of the key drivers that are expected to boost the growth of the global stem cell assay market are:
  • The increasing adoption of stem cell-based therapies for various diseases, such as cancer, diabetes, neurological disorders, cardiovascular diseases, and autoimmune disorders. According to the International Society for Stem Cell Research (ISSCR), there are more than 1000 clinical trials using stem cells worldwide, and the number is expected to increase in the coming years.
  • The rising funding and support from governments and private organizations for stem cell research and development. For instance, the National Institutes of Health (NIH) in the US allocated USD 2.2 billion for stem cell research in 2020, an increase of 8.5% from 2019. Similarly, the European Commission funded EUR 1.3 billion for stem cell research under the Horizon 2020 program from 2014 to 2020.
  • The technological advancements and innovations in stem cell assay, such as the development of novel platforms, biomarkers, and tools for stem cell characterization, isolation, and expansion. For example, in 2019, a team of researchers from the University of California, Los Angeles (UCLA) developed a new method to create stem cells from blood cells using a single gene. The method, called reprogramming factor-mediated conversion (RFMC), is faster, simpler, and more efficient than the conventional methods of stem cell generation.
Some of the key constraints that are expected to hamper the growth of the global stem cell assay market are:
  • The ethical and regulatory issues related to the use of stem cells, especially embryonic stem cells, which are derived from human embryos. The use of embryonic stem cells is controversial, as it involves the destruction of potential human life and raises questions about the rights and dignity of the embryo. Different countries have different laws and regulations regarding the use of embryonic stem cells, which creates challenges for the global stem cell assay market.
  • The high cost of stem cell products and services, which limits the affordability and accessibility of stem cell-based therapies for many patients. The cost of stem cell therapy can range from USD 5,000 to USD 100,000, depending on the type, source, and quality of stem cells, the complexity and duration of the procedure, and the location and reputation of the clinic. The cost of stem cell assay can also vary depending on the type, format, and scale of the assay, the equipment and reagents required, and the expertise and labor involved.
  • The lack of standardized procedures and infrastructure for stem cell assay, which affects the quality, reliability, and reproducibility of the results. Stem cell assay is a complex and dynamic process that requires specialized skills, equipment, and protocols. However, there is no universal consensus or guideline for stem cell assay, which leads to variations and inconsistencies in the methods, parameters, and outcomes of the assay. This also poses challenges for the comparison and validation of the data across different studies and laboratories.

Global Stem Cell Assay Market Trends and Developments

The global stem cell assay market has been witnessing several key trends and developments in recent years:
  • Technological Advancements: There has been a surge in technological innovations in stem cell assays, including the development of high-throughput screening methods, automation, and advanced imaging techniques. These advancements have improved the efficiency and accuracy of stem cell research and assays.
  • Increased Focus on Regenerative Medicine: The growing interest in regenerative medicine and its potential to treat various chronic diseases has fueled the demand for stem cell assays. These assays are crucial for understanding stem cell behavior, differentiation, and therapeutic efficacy.
  • Expansion of Applications: Stem cell assays are being used in a broader range of applications, including drug discovery, toxicity testing, and personalized medicine. The ability to use stem cells to model diseases and test drug responses is driving the expansion of the market.
  • Rising Investment in Stem Cell Research: Governments and private organizations are increasing their funding for stem cell research, which is driving the growth of the stem cell assay market. This investment is supporting the development of new assays and the expansion of research activities.
  • Emergence of 3D Cell Culture Models: 3D cell culture models, including organoids and spheroids, are gaining popularity in stem cell assays. These models better mimic the in vivo environment, providing more physiologically relevant data for stem cell research and drug development.
  • Collaborations and Partnerships: Companies in the stem cell assay market are increasingly collaborating and forming partnerships to leverage each other's expertise and resources. These collaborations are aimed at developing innovative products and expanding market reach.
  • Growing Use of Induced Pluripotent Stem Cells (iPSCs): iPSCs are being widely used in stem cell assays due to their ability to differentiate into various cell types. The use of iPSCs in disease modeling, drug discovery, and regenerative medicine is a significant trend in the market.
  • Advancements in Biomarker Identification: The identification of novel biomarkers for stem cell characterization and differentiation is an ongoing trend. These biomarkers are crucial for the development of more specific and sensitive stem cell assays.
  • Regulatory Developments: Regulatory authorities are providing guidelines and frameworks for stem cell research and its applications, which is influencing the development and standardization of stem cell assays.
Overall, the global stem cell assay market is evolving rapidly, with technological innovations, expanding applications, and increasing investment driving its growth and development.

Global Stem Cell Assay Market Segmentation

Market Breakup by Product Type

  • Kits and Reagents
  • Instruments
  • Services

Market Breakup by Technology

  • Flow Cytometry
  • High-Content Screening
  • PCR
  • Spectrophotometry
  • Microarray
  • Other Technologies

Market Breakup by Assay Type

  • Viability/Cytotoxicity Assays
  • Isolation/Purification Assays
  • Differentiation Assays
  • Proliferation Assays
  • Apoptosis Assays
  • Other Assay Types

Market Breakup by Cell Type

  • Adult Stem Cells
  • Embryonic Stem Cells
  • Induced Pluripotent Stem Cells (iPSCs)

Market Breakup by Application

  • Drug Discovery and Development
  • Regenerative Medicine and Therapy Development
  • Clinical Research
  • Other Applications

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Stem Cell Assay Market Competitive Landscape

The competitive landscape of the global biobanking market is fragmented, with several players operating in various regions. Some of the key players in the market Thermo Fisher Scientific Inc., Merck KGaA (Sigma-Aldrich), PerkinElmer, Inc., GE Healthcare, Bio-Rad Laboratories, Inc., STEMCELL Technologies Inc., Cell Biolabs, Inc., Promega Corporation, Lonza Group, Miltenyi Biotec, Cell Signaling Technology, Inc., Agilent Technologies, Inc., R&D Systems (a Bio-Techne brand), Bio-Techne Corporation and Cytiva (formerly GE Healthcare Life Sciences).

These players offer a range of products and services for biobanking, such as consumables, equipment, software, and storage solutions. They also compete on the basis of innovation, quality, price, and customer service. The market is expected to witness high growth opportunities in emerging regions, such as Latin America and Middle East and Africa, where the demand for biobanking is increasing due to the rising prevalence of chronic diseases, the growing awareness of personalized medicine, and the expanding research activities in the life sciences sector.

This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Stem Cell Assay Market Overview
3.1 Global Stem Cell Assay Market Historical Value (2017-2023)
3.2 Global Stem Cell Assay Market Forecast Value (2024-2032)
4 Global Stem Cell Assay Market Landscape*
4.1 Global Stem Cell Assay: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Stem Cell Assay: Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Technology
5 Global Stem Cell Assay Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Stem Cell Assay Market Segmentation (2017-2032)
6.1 Global Stem Cell Assay Market (2017-2032) by Product Type
6.1.1 Market Overview
6.1.2 Kits and Reagents
6.1.3 Instruments
6.1.4 Services
6.2 Global Stem Cell Assay Market (2017-2032) by Technology
6.2.1 Market Overview
6.2.2 Flow Cytometry
6.2.3 High-Content Screening
6.2.4 PCR
6.2.5 Spectrophotometry
6.2.6 Microarray
6.2.7 Other Technologies
6.3 Global Stem Cell Assay Market (2017-2032) by Assay Type
6.3.1 Market Overview
6.3.2 Viability/Cytotoxicity Assays
6.3.3 Isolation/Purification Assays
6.3.4 Differentiation Assays
6.3.5 Proliferation Assays
6.3.6 Apoptosis Assays
6.3.7 Other Assay Types
6.4 Global Stem Cell Assay Market (2017-2032) by Cell Type
6.4.1 Market Overview
6.4.2 Adult Stem Cells
6.4.3 Embryonic Stem Cells
6.4.4 Induced Pluripotent Stem Cells (iPSCs)
6.5 Global Stem Cell Assay Market (2017-2032) by Application
6.5.1 Market Overview
6.5.2 Drug Discovery and Development
6.5.3 Regenerative Medicine and Therapy Development
6.5.4 Clinical Research
6.5.5 Other Applications
6.6 Global Stem Cell Assay Market (2017-2032) by End User
6.6.1 Market Overview
6.6.2 Pharmaceutical and Biotechnology Companies
6.6.3 Research Institutes
6.6.4 Contract Research Organizations (CROs)
6.6.5 Other End Users
6.7 Global Stem Cell Assay Market (2017-2032) by Region
6.7.1 Market Overview
6.7.2 North America
6.7.3 Europe
6.7.4 Asia Pacific
6.7.5 Latin America
6.7.6 Middle East and Africa
7 North America Stem Cell Assay Market (2017-2032)
7.1 North America Stem Cell Assay Market (2017-2032) by Product Type
7.1.1 Market Overview
7.1.2 Kits and Reagents
7.1.3 Instruments
7.1.4 Services
7.2 North America Stem Cell Assay Market (2017-2032) by Technology
7.2.1 Market Overview
7.2.2 Flow Cytometry
7.2.3 High-Content Screening
7.2.4 PCR
7.2.5 Spectrophotometry
7.2.6 Microarray
7.2.7 Other Technologies
7.3 North America Stem Cell Assay Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Stem Cell Assay Market (2017-2032)
8.1 Europe Stem Cell Assay Market (2017-2032) by Product Type
8.1.1 Market Overview
8.1.2 Kits and Reagents
8.1.3 Instruments
8.1.4 Services
8.2 Europe Stem Cell Assay Market (2017-2032) by Technology
8.2.1 Market Overview
8.2.2 Flow Cytometry
8.2.3 High-Content Screening
8.2.4 PCR
8.2.5 Spectrophotometry
8.2.6 Microarray
8.2.7 Other Technologies
8.3 Europe Stem Cell Assay Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Stem Cell Assay Market (2017-2032)
9.1 Asia Pacific Stem Cell Assay Market (2017-2032) by Product Type
9.1.1 Market Overview
9.1.2 Kits and Reagents
9.1.3 Instruments
9.1.4 Services
9.2 Asia Pacific Stem Cell Assay Market (2017-2032) by Technology
9.2.1 Market Overview
9.2.2 Flow Cytometry
9.2.3 High-Content Screening
9.2.4 PCR
9.2.5 Spectrophotometry
9.2.6 Microarray
9.2.7 Other Technologies
9.3 Asia Pacific Stem Cell Assay Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Stem Cell Assay Market (2017-2032)
10.1 Latin America Stem Cell Assay Market (2017-2032) by Product Type
10.1.1 Market Overview
10.1.2 Kits and Reagents
10.1.3 Instruments
10.1.4 Services
10.2 Latin America Stem Cell Assay Market (2017-2032) by Technology
10.2.1 Market Overview
10.2.2 Flow Cytometry
10.2.3 High-Content Screening
10.2.4 PCR
10.2.5 Spectrophotometry
10.2.6 Microarray
10.2.7 Other Technologies
10.3 Latin America Stem Cell Assay Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Stem Cell Assay Market (2017-2032)
11.1 Middle East and Africa Stem Cell Assay Market (2017-2032) by Product Type
11.1.1 Market Overview
11.1.2 Kits and Reagents
11.1.3 Instruments
11.1.4 Services
11.2 Middle East and Africa Stem Cell Assay Market (2017-2032) by Technology
11.2.1 Market Overview
11.2.2 Flow Cytometry
11.2.3 High-Content Screening
11.2.4 PCR
11.2.5 Spectrophotometry
11.2.6 Microarray
11.2.7 Other Technologies
11.3 Middle East and Africa Stem Cell Assay Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Thermo Fisher Scientific Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Merck KGaA (Sigma-Aldrich)
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 PerkinElmer, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 GE Healthcare
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Bio-Rad Laboratories, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 STEMCELL Technologies Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Cell Biolabs, Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Promega Corporation
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Lonza Group
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Miltenyi Biotec
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Cell Signaling Technology, Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Agilent Technologies, Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 R&D Systems (a Bio-Techne brand)
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Bio-Techne Corporation
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Cytiva (formerly GE Healthcare Life Sciences)
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
List not exhaustive
18 Global Stem Cell Assay Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The research team strives to make this section as comprehensive as possible.

Companies Mentioned

  • Thermo Fisher Scientific Inc.
  • Merck KGaA (Sigma-Aldrich)
  • PerkinElmer, Inc.
  • GE Healthcare
  • Bio-Rad Laboratories, Inc.
  • STEMCELL Technologies Inc.
  • Cell Biolabs, Inc.
  • Promega Corporation
  • Lonza Group
  • Miltenyi Biotec
  • Cell Signaling Technology, Inc.
  • Agilent Technologies, Inc.
  • R&D Systems (a Bio-Techne brand)
  • Bio-Techne Corporation
  • Cytiva (formerly GE Healthcare Life Sciences)